BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BBOT • US1079241022

10.68 USD
-0.02 (-0.19%)
At close: Feb 9, 2026
10.7 USD
+0.02 (+0.19%)
After Hours: 2/9/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

BBOT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. BBOT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BBOT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year BBOT was profitable.
  • BBOT had a negative operating cash flow in the past year.
BBOT Yearly Net Income VS EBIT VS OCF VS FCFBBOT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M 4M 6M

1.2 Ratios

  • The Return On Assets of BBOT (2.39%) is better than 89.29% of its industry peers.
  • Looking at the Return On Equity, with a value of 2.49%, BBOT belongs to the top of the industry, outperforming 90.25% of the companies in the same industry.
Industry RankSector Rank
ROA 2.39%
ROE 2.49%
ROIC N/A
ROA(3y)-3.68%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBOT Yearly ROA, ROE, ROICBBOT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BBOT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBOT Yearly Profit, Operating, Gross MarginsBBOT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • BBOT has more shares outstanding than it did 1 year ago.
  • BBOT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBOT Yearly Shares OutstandingBBOT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
BBOT Yearly Total Debt VS Total AssetsBBOT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • BBOT has an Altman-Z score of 62.77. This indicates that BBOT is financially healthy and has little risk of bankruptcy at the moment.
  • BBOT has a better Altman-Z score (62.77) than 97.32% of its industry peers.
  • BBOT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 62.77
ROIC/WACCN/A
WACCN/A
BBOT Yearly LT Debt VS Equity VS FCFBBOT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • BBOT has a Current Ratio of 0.33. This is a bad value and indicates that BBOT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BBOT's Current ratio of 0.33 is on the low side compared to the rest of the industry. BBOT is outperformed by 91.59% of its industry peers.
  • A Quick Ratio of 0.33 indicates that BBOT may have some problems paying its short term obligations.
  • BBOT has a Quick ratio of 0.33. This is amonst the worse of the industry: BBOT underperforms 91.20% of its industry peers.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.33
BBOT Yearly Current Assets VS Current LiabilitesBBOT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 17.40% over the past year.
EPS 1Y (TTM)17.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BBOT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -109.44% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1076.54%
EPS Next 2Y-192.84%
EPS Next 3Y-109.44%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BBOT Yearly EPS VS EstimatesBBOT Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 53.40, BBOT can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, BBOT is valued cheaply inside the industry as 90.82% of the companies are valued more expensively.
  • BBOT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.06.
  • The Forward Price/Earnings Ratio is negative for BBOT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 53.4
Fwd PE N/A
BBOT Price Earnings VS Forward Price EarningsBBOT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBOT Per share dataBBOT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • A cheap valuation may be justified as BBOT's earnings are expected to decrease with -109.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-192.84%
EPS Next 3Y-109.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BBOT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRIDGEBIO ONCOLOGY THERAPEUT

NASDAQ:BBOT (2/9/2026, 8:00:01 PM)

After market: 10.7 +0.02 (+0.19%)

10.68

-0.02 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-03
Inst Owners68.02%
Inst Owner Change0.32%
Ins Owners0.11%
Ins Owner Change5.96%
Market Cap854.29M
Revenue(TTM)N/A
Net Income(TTM)4.72M
Analysts86.15
Price Target24.63 (130.62%)
Short Float %3.75%
Short Ratio8.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.47%
PT rev (3m)-0.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)3.56%
EPS NY rev (3m)-59.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 53.4
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.51
P/tB 4.51
EV/EBITDA N/A
EPS(TTM)0.2
EY1.87%
EPS(NY)-2.35
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS2.37
TBVpS2.37
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.26
Profitability
Industry RankSector Rank
ROA 2.39%
ROE 2.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3.68%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.33
Altman-Z 62.77
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.45%
EPS Next Y-1076.54%
EPS Next 2Y-192.84%
EPS Next 3Y-109.44%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1399.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26799.7%
EBIT Next 3Y-649.09%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BRIDGEBIO ONCOLOGY THERAPEUT / BBOT FAQ

What is the fundamental rating for BBOT stock?

ChartMill assigns a fundamental rating of 2 / 10 to BBOT.


What is the valuation status of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIDGEBIO ONCOLOGY THERAPEUT (BBOT). This can be considered as Overvalued.


How profitable is BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?

BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) has a profitability rating of 2 / 10.


What are the PE and PB ratios of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?

The Price/Earnings (PE) ratio for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 53.4 and the Price/Book (PB) ratio is 4.51.


How financially healthy is BRIDGEBIO ONCOLOGY THERAPEUT?

The financial health rating of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 5 / 10.